Gsk Plc-spon Adr. Earnings

Gsk Plc-spon Adr.’s revenue fell -0.5% since last year same period to $8012Mn in the Q3 2024. On a quarterly growth basis, Gsk Plc-spon Adr. has generated 0% jump in its revenue since last 3-months.

Gsk Plc-spon Adr.’s net profit fell -116.57% since last year same period to $-58Mn in the Q3 2024. On a quarterly growth basis, Gsk Plc-spon Adr. has generated 0% jump in its net profits since last 3-months.

Gsk Plc-spon Adr.’s net profit margin fell -116.65% since last year same period to -0.72% in the Q3 2024. On a quarterly growth basis, Gsk Plc-spon Adr. has generated 0% jump in its net profit margins since last 3-months.

Gsk Plc-spon Adr.’s price-to-earnings ratio after this Q3 2024 earnings stands at 21.71.

Gsk Plc-spon Adr.’s earning per share (EPS) estimates for the current quarter stand at 1.23 - a 24.24% jump from last quarter’s estimates.

Gsk Plc-spon Adr.’s earning per share (EPS) estimates for the current year stand at 1.23.

Gsk Plc-spon Adr.’s earning per share (EPS) jumped 0.78% since last year same period to 1.29 in the Q3 2024. This indicates that the Gsk Plc-spon Adr. has generated 0.78% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Gsk Plc-spon Adr.’s return on assets (ROA) stands at 0.07.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Gsk Plc-spon Adr.’s return on equity (ROE) stands at 0.22.

Gsk Plc-spon Adr. declared 0.39 dividend per share during the earnings announcement for Q3 2024.